Overall Survival Benefit With Upfront Daratumumab Plus Lenalidomide/Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
In an updated analysis of the phase III MAIA trial, the addition of daratumumab to lenalidomide and dexamethasone resulted...
Adjuvant Platinum vs Capecitabine in Patients With Basal Subtype Triple-Negative Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy
As reported in the Journal of Clinical Oncology and during the 2021 ASCO Annual Meeting by Ingrid A. Mayer, MD, and colleagues...
Venetoclax Plus FLAG-IDA Induction and Consolidation for AML
In a single-institution phase I/II study reported in the Journal of Clinical Oncology, Courtney D. DiNardo, MD, and colleagues found...
Pralsetinib in Advanced RET Fusion–Positive NSCLC: ARROW Trial
As reported in The Lancet Oncology by Justin F. Gainor, MD, and colleagues, an interim analysis of the phase I/II ARROW trial...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Farhad Ravandi: How MRD Assessment May Help Guide Treatment Selection for Patients With AML
Sara Hurvitz on Margetuximab-cmkb in HER2-Positive Breast Cancer
Dawn Hershman on The Evolving Focus of Cardio-oncology
Nagi El Saghir: Virtual Meetings Are Here to Stay
Dan Zandberg on Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Sponsored Content
Sponsored by Puma Biotechnology
Adjuvant Therapy in HER2-Positive, Hormone Receptor–Positive Breast Cancer
High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma
Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, were presented by Grossmann et al...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Venetoclax Plus FLAG-IDA Induction and Consolidation for AML
In a single-institution phase I/II study reported in the Journal of Clinical Oncology, Courtney D. DiNardo, MD, and colleagues found that the combination of venetoclax with FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) in induction and consolidation...
High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma
Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, were presented by Grossmann et al...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Extended Follow-up of Nivolumab/Ipilimumab for Metastatic Melanoma
In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive at a median of 6.5 years after treatment. These long-term results from the...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
